Fig. 2From: Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritisComparison of mean CDAI across 4 clusters among subjects using linked EHR and RA registry data for 6 years following first b/tsDMARD prescriptionBack to article page